SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease
By Lori Solomon HealthDay Reporter
THURSDAY, May 2, 2024 -- Use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) is associated with a substantially lower risk for dialysis and cardiovascular disease in patients with type 2 diabetes (T2D) and stage 5 chronic kidney disease (CKD), according to a study published online April 30 in the Annals of Internal Medicine.
Fu-Shun Yen, M.D., from Dr. Yen's Clinic in Taoyuan, Taiwan, and colleagues used the Taiwan National Health Insurance Research Database to identify 23,854 SGLT2i users and 23,892 SGLT2i nonusers with T2D and stage 5 CKD (from May 1, 2016, to Oct. 31, 2021).
The researchers found that compared with no SGLT2i use, SGLT2i use was associated with lower risks for dialysis (hazard ratio [HR], 0.34; 95 percent confidence interval [CI], 0.27 to 0.43), hospitalization for heart failure (HR, 0.80; 95 percent CI, 0.73 to 0.86), acute myocardial infarction (HR, 0.61; 95 percent CI, 0.52 to 0.73), diabetic ketoacidosis (HR, 0.78; 95 percent CI, 0.71 to 0.85), and acute kidney injury (HR, 0.80; 95 percent CI, 0.70 to 0.90). No differences were seen for the risk for all-cause mortality (HR, 1.11; 95 percent CI, 0.99 to 1.24). A lower risk for long-term dialysis was also seen for initiation of an SGLT2i in stage 5 CKD.
"Sodium-glucose cotransporter-2 inhibitors are likely to be a cornerstone in managing patients at different stages of CKD to reduce the risk for dialysis and cardiovascular disease," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 -- For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists...
Risk for Kidney Complications Increased After Heart Failure Hospitalization
WEDNESDAY, June 5, 2024 -- Older adults with heart failure have considerable risk for kidney complications, with 6 percent progressing to dialysis at one year after...
Diabetes Tied to Higher Prevalence of Overactive Bladder
TUESDAY, June 4, 2024 -- Markers of diabetes are positively associated with overactive bladder (OAB), according to a study published online April 28 in Frontiers in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.